Berberine containing quadruple therapy for initial Helicobacter Pylori eradication

Berberine containing quadruple therapy for initial Helicobacter Pylori eradication - Berberine containing therapy for Helicobacter Pylori

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033829

Enrollment

100

Registered

2018-08-20

Start date

2018-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection

Interventions

Berberine Containing Therapy (Berberine 0.3g tid, Rabeprazole 10mg bid, Bismuth 500mg bid, Amoxicillin 1g bid and Clarithromycin 500mg bid) for 14 days Bismuth Containing Quadruple Therapy (Rabeprazol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients positive to Rapid Urease Test Patients positive to 13C Urease Breath Test Patients verified of Hp infection with pathology

Exclusion criteria

Exclusion criteria: Patients with allergy history of drugs medicated in this trail Patients with history of hepatic or/and renal dysfunction Patients with history of operation on upper digestive tract Patients with alcoholism and drug abuse Patients in pregnancy or lactation Patients who ever participated other clinical trials in latest 3 months Patients with previous eradication therapy;

Design outcomes

Primary

Measure	Time frame
eradication rate of H. pylori	—

Secondary

Measure	Time frame
side effects rate during therapy	—

Countries

Asia(except Japan)

Contacts

Public ContactXiaobei Si

Beijing Jishuitan Hospital Departement of Gastroenterology

sixiaobei2008@126.com86-10-58398289

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026